BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 19293771)

  • 1. PET-CT for treatment planning in prostate cancer.
    Picchio M; Crivellaro C; Giovacchini G; Gianolli L; Messa C
    Q J Nucl Med Mol Imaging; 2009 Apr; 53(2):245-68. PubMed ID: 19293771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evidence on PET/CT for radiation therapy planning in prostate cancer.
    Picchio M; Giovannini E; Crivellaro C; Gianolli L; di Muzio N; Messa C
    Radiother Oncol; 2010 Sep; 96(3):347-50. PubMed ID: 20708811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET/CT and radiotherapy in prostate cancer.
    De Jong IJ; De Haan TD; Wiegman EM; Van Den Bergh AC; Pruim J; Breeuwsma AJ
    Q J Nucl Med Mol Imaging; 2010 Oct; 54(5):543-52. PubMed ID: 20927021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP).
    Panebianco V; Sciarra A; Lisi D; Galati F; Buonocore V; Catalano C; Gentile V; Laghi A; Passariello R
    Eur J Radiol; 2012 Apr; 81(4):700-8. PubMed ID: 21330082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer.
    Tuncel M; Souvatzoglou M; Herrmann K; Stollfuss J; Schuster T; Weirich G; Wester HJ; Schwaiger M; Krause BJ
    Nucl Med Biol; 2008 Aug; 35(6):689-95. PubMed ID: 18678354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
    J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET/CT and choline: diagnosis and staging.
    Farsad M; Schwarzenböck S; Krause BJ
    Q J Nucl Med Mol Imaging; 2012 Aug; 56(4):343-53. PubMed ID: 23013664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron emission tomography for prostate, bladder, and renal cancer.
    Schöder H; Larson SM
    Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of PET/computed tomography scan in the management of prostate cancer.
    Picchio M; Giovannini E; Messa C
    Curr Opin Urol; 2011 May; 21(3):230-6. PubMed ID: 21378572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis.
    Farsad M; Schiavina R; Castellucci P; Nanni C; Corti B; Martorana G; Canini R; Grigioni W; Boschi S; Marengo M; Pettinato C; Salizzoni E; Monetti N; Franchi R; Fanti S
    J Nucl Med; 2005 Oct; 46(10):1642-9. PubMed ID: 16204714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen kinetics and choline PET/CT in patients with biochemical relapse after primary treatment for prostate cancer.
    Castellucci P; Fuccio C; Marzola MC; Al-Nahhas A; Rubello D; Fanti S
    Nucl Med Commun; 2011 Jun; 32(6):475-8. PubMed ID: 21394046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases.
    Budiharto T; Joniau S; Lerut E; Van den Bergh L; Mottaghy F; Deroose CM; Oyen R; Ameye F; Bogaerts K; Haustermans K; Van Poppel H
    Eur Urol; 2011 Jul; 60(1):125-30. PubMed ID: 21292388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Choline-PET in prostate cancer management: the point of view of the radiation oncologist.
    De Bari B; Alongi F; Lestrade L; Giammarile F
    Crit Rev Oncol Hematol; 2014 Sep; 91(3):234-47. PubMed ID: 24813466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer.
    Seltzer MA; Barbaric Z; Belldegrun A; Naitoh J; Dorey F; Phelps ME; Gambhir SS; Hoh CK
    J Urol; 1999 Oct; 162(4):1322-8. PubMed ID: 10492189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot comparison of F-fluorocholine and F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer.
    Beauregard JM; Williams SG; Degrado TR; Roselt P; Hicks RJ
    J Med Imaging Radiat Oncol; 2010 Aug; 54(4):325-32. PubMed ID: 20718912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restaging prostate cancer patients with biochemical failure with PET/CT and radiolabeled choline.
    Giovacchini G; Breeuwsma AJ
    Q J Nucl Med Mol Imaging; 2012 Aug; 56(4):354-66. PubMed ID: 23013665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative detection of prostate cancer: a comparison with 11C-choline PET, 18F-fluorodeoxyglucose PET and MR imaging.
    Watanabe H; Kanematsu M; Kondo H; Kako N; Yamamoto N; Yamada T; Goshima S; Hoshi H; Bae KT
    J Magn Reson Imaging; 2010 May; 31(5):1151-6. PubMed ID: 20432351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of PET and PET/CT on treatment planning and prognosis of patients with NSCLC treated with radiation therapy.
    Nawara C; Rendl G; Wurstbauer K; Lackner B; Rettenbacher L; Datz L; Studnicka M; Sedlmayer F; Pirich C
    Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):191-201. PubMed ID: 22402822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary.
    Han A; Xue J; Hu M; Zheng J; Wang X
    Cancer Epidemiol; 2012 Oct; 36(5):470-5. PubMed ID: 22504050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.